Hope for Biologic Treatment of Hidradenitis Suppurativa
Feb 01, 2023
Recent News
Read ArticleA meta-analysis of trials using biologics [adalimumab (ADA), ustekinumab (UST) and secukinumab (SEC)] in the the management of hidradenitis suppurativa (HS) suggests promising results, but more controlled, rigorous studies are needed.
While only adalimumab is currently FDA approved for this inflammatory skin disorder, numerous trials with other biologics exist or are in progress.
ACR Urges CMS to Reconsider Copay Assistant Programs in CMS Proposed Rule
Feb 01, 2023
The Health and Human Services Notice of Benefit and Payment Parameters proposed rule for 2024 does not revise policies related to copay assistance and patient deductibles.
Read Article
Studies in 76 systemic sclerosis (SSc) pts (& animal models of SSc) show fibroblast A20 (enzyme) is downregulated and promotes fibrosis in SSc; but is repressed by DREAM, an A20 negative transcriptional regulator. https://t.co/30PuO4XRuq https://t.co/VJuAJHGbut
Feb 01, 2023
Join us at RheumNow Live this March!
Dr. Janet Pope ( @janetbirdnope) will be back to discuss decisive therapeutics in RA.https://t.co/0IkJsGpH6s https://t.co/TwM6AAW97X
Links:
Feb 01, 2023
US population mortality rates compared dermatomyositis (DM) vs polymyositis (PM) in 1981 (12,249) & 2020 (23,608). Downward trend in DM/PM mortality (<7%); plus PM/DM was 2X more likely to be one of mult causes, instead of, sole cause of death. https://t.co/9KZKr8JxUE https://t.co/7acK0eHVku
Links:
Feb 01, 2023
Systematic review of MRI confirm degenerative meniscus tears compared arthroscopic meniscectomy (APM) vs non-surgical or sham Rx. Results: 10 trials, 605 patients showed at 24 mos F/U, no advantage in Function or QOL favoring APM - rec conservative Rx https://t.co/4CwicQ9Jac https://t.co/3IrSRkNgqp
Links:
Feb 01, 2023
How do you treat latent TB? This and more on last week's RheumNow podcast.https://t.co/4gUXFUDTFM https://t.co/TgT6ZyewZJ
Links:
Feb 01, 2023
Can something as simple as a cup of coffee with milk have an anti-inflammatory effect in humans?
Apparently so, according to a new study. A combination of proteins and antioxidants doubles the anti-inflammatory properties. https://t.co/As8lhxnifp https://t.co/eZKD8Y6oTx
Links:
Feb 01, 2023
Herpes Zoster with JAK Inhibitors
Jan 31, 2023
JAK inhibitors are approved for several immune-mediated inflammatory diseases and carry a higher than usual risk of herpes zoster in certain conditions like rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis.
Read Article
Amgen launched its adalimumab biosimilar - Amjevita ( FDA approved in 2016), has 2 different discounts— 55% or 5% below Humira's (list $6,922/mo). Another report says Amjevita 40mg given q 2wk will cost $40,497 - $85,494 annually https://t.co/iGtJUa991N https://t.co/PTPTUskUaa
Links:
Jan 31, 2023
1st there was combined Rheum-Derm or Rheum-Pulm clinics. Medscape reports new Rheum-Cardiology clinics at Cleveland Clinic, NYU, Brigham, Stanford. Useful in research, managing Rheum pts a) at hi CV risk, B) having procedures/surgery, c) risk reduction https://t.co/9AqujArSMT https://t.co/3ZVORt9gK9
Links:
Jan 31, 2023
FDA has approved the 1st BTK (Bruton’s tyrosine kinase) inhibitor (Jaypirca™ or pirtobrutinib) for adults with refractory mantle cell lymphoma. BTK inhibitors are also being developed for use in MS, RA, SLE, pemphigus & more https://t.co/gDHbcDpNnT https://t.co/oL0nldQ1fN
Links:
Jan 31, 2023
Last day for early bird pricing!https://t.co/KwQnDC4Pdz
RheumNow Live is a 1.5-day long meeting that offers pre-learning modules, shorter, concise lectures with clinical context and audience input, more discussion time, and sessions that are relaxed and comprehensive. https://t.co/W4mqIyhgRS
Links:
Jan 31, 2023
Have you listened to last week's RheumNow podcast?
Dr. Cush answers the question--is there such a thing as dry synovitis?https://t.co/Um0JhCfRDv https://t.co/rXOGWOEnlr
Links:
Jan 31, 2023
Pathogenic Impact of microRNA Cotargeting in Lupus
A group of researchers from the Graduate School of Medicine at Nagoya University in Japan have discovered the impact of microRNA (miRNA) on inflammation in lupus in mice. https://t.co/j0TRgIaam6 https://t.co/HNJbsTfT7c
Links:
Jan 31, 2023
Women at high risk of fracture remain untreated for osteoporosis
EurekAlert!
Jan 30, 2023
An estimated 100,000 to 120,000 fragility fractures occur annually in the Netherlands, the equivalent of at least 11 broken bones per hour. The cause is osteoporosis, a disease in which the skeleton becomes weak and fragile, leading to potentially devastating fractures that result in disability, loss of independence and premature death for some sufferers.
Read Article
Study of 58 pediatric patients with Kikuchi-Fujimoto disease saw 15 (26%) with Macrophage Activation Syndr. KFD-MAS+ pts had signif. more skin rash (27%), Steroid Rx(80%), Dz recurrence (33%), lower cell counts (WBC, plt, lymphs) & higher LDH. https://t.co/GINlAJlEHi https://t.co/idhuaAo9T6
Links:
Jan 30, 2023
197 ANCA assoc Vasculitis pts in RAVE - treated w/ RTX or CTX, thenAZA. 18/22 severe infections occurred within 6 months. Predictors of severe infx included higher baseline CD19+B cells & PJP prophylaxis w/ TMP/SMX (both groups Rx RTX or CYC/AZA) https://t.co/YhNDCdJuof https://t.co/Fg8AOLtYbI
Links:
Jan 30, 2023
Advancing Telehealth in Rheumatology https://t.co/XZTkGQMImc https://t.co/QJjXzjAx5Q
Links:
Jan 30, 2023
Rheumatic Disease - IBD Overlap
Nearly one in 10 patients with IBD also have rheumatologic disorders, meaning that specialists have to talk to each other to develop a treatment plan that works for both conditions, a researcher suggested. https://t.co/s3u9q8Sw9Y https://t.co/RjFyEcm6FA
Links:
Jan 30, 2023
AI Passes U.S. Medical Licensing Exam
Two artificial intelligence (AI) programs -- including ChatGPT -- have passed the U.S. Medical Licensing Examination (USMLE), according to two recent papers. https://t.co/E5GEWrJR00 https://t.co/nd9PrLVn4U
Links:
Jan 30, 2023
From the blog
Bad Stress
Jan 31, 2023
“Bad is stronger than good.”
Wait, bad is bad, right?
No good should come of bad. But if you reconsider bad, it could be a challenge, and not a pothole. Success and great opportunity are often the rebound to adversity (bad) or failure. Yet, for most, bad drives the story we tell ourselves; a deflating spin of negativism that is sticky or inescapable.
For you, bad happenings this week could be the rebound motivator for tomorrow’s solutions. If your past informs your future, then your “bad” can certainly improve your future.
Podcasts
Simon Says “Don’t Do This” (1.27.2023)Jan 27, 2023- The RheuNow Podcast Preview - Til Death Do Us Part (1.20.2023)Jan 20, 2023
- Rheum Believe It Or Not (1.13.2023)Jan 13, 2023
- RheumNow Podcast- 2022 Rheumatology Year in ReviewJan 06, 2023
